First Oral Drug for Moderate-To-Severe Ulcerative Colitis

被引：0
|
作者：
Aschenbrenner, Diane S.
机构：
来源：
AMERICAN JOURNAL OF NURSING | 2018年 / 118卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Immediate-release tofacitinib (Xeljanz) is now approved to treat moderate-to-severe ulcerative colitis. Nurses should assess patients for infections prior to the initiation of and throughout tofacitinib treatment.
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [21] Cytomegalovirus colitis in patients with moderate-to-severe Ulcerative Colitis: diagnosis, clinical impact and treatment efficacy
    Melotti, L.
    Salice, M.
    Rinaldi, M.
    Dussias, N.
    Vanigli, N.
    Scaioli, E.
    Hrustemovic, H. Privitera
    Rizzello, F.
    Gionchetti, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I567 - I568
  • [22] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND
    Sruamsiri, R.
    [J]. VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [23] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    [J]. GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
  • [24] Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
    Wu, Bin
    Wang, Zhenhua
    Zhang, Qiang
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2291 - 2302
  • [25] Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis
    Sandborn, William
    Van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas
    Kron, Martina
    Tighe, Mary
    Lazar, Andreas
    Thakkar, Roopal
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S3 - S4
  • [26] Addition of leukocytapheresis to steroid therapy - Is it beneficial in recurrence of moderate-to-severe ulcerative colitis?
    Jo, Y
    Matsumoto, T
    Mibu, R
    Iida, M
    [J]. DISEASES OF THE COLON & RECTUM, 2003, 46 (10) : S3 - S9
  • [27] Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
    Fischer, A.
    Oppe, M.
    Stypa, S.
    Lukyanov, V.
    Petrakis, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S387 - S387
  • [28] First JAK Inhibitor approved for moderate to severe Ulcerative Colitis
    Fessler, Beate
    [J]. VISCERAL MEDICINE, 2018, 34 (05) : 398 - 398
  • [29] A critical review of adalimumab for the treatment of moderate-to-severe active ulcerative colitis in children
    Pigneur, Benedicte
    Ruemmele, Frank M.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (11-12) : 1023 - 1028
  • [30] Treatment Patterns Among Patients With Moderate-to-Severe Ulcerative Colitis in the United States
    DiBonaventura, Marco
    Bargo, Danielle
    Lucas, James
    Bluff, Daniel
    Hoskin, Ben
    Salese, Leonardo
    Cappelleri, Joseph C.
    Quirk, Daniel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S353 - S353
12345